Atlas Trials

Protocol for Herceptin as Adjuvant Therapy With Reduced Exposure to Chemotherapy (PHARE-C)

Clinical trial NCT05388500 · NOT_YET_RECRUITING

Trial details

NCT number
NCT05388500
Sponsor
Institut de cancérologie Strasbourg Europe
Status
NOT_YET_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
HER2-positive Breast Cancer
Start date
2022-12-15
Primary completion
2030-12-15
Enrollment
800

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.